Spondylodiscitis caused by Candida krusei: case report and susceptibility patterns

J Clin Microbiol. 2006 May;44(5):1912-4. doi: 10.1128/JCM.44.5.1912-1914.2006.

Abstract

A 62-year-old man with amphotericin B-resistant Candida krusei spondylodiscitis, following an episode of candidemia caused by the same strain, was successfully treated with caspofungin plus voriconazole. Amphotericin B fungicidal concentrations were better predictors of the clinical outcome than were MICs. This is the first case of C. krusei spondylodiscitis reported in the literature.

Publication types

  • Case Reports

MeSH terms

  • Amphotericin B / therapeutic use
  • Antifungal Agents / therapeutic use
  • Candida / classification
  • Candida / drug effects
  • Candida / isolation & purification
  • Candida / pathogenicity*
  • Candidiasis / diagnosis
  • Candidiasis / etiology*
  • Candidiasis / microbiology
  • Caspofungin
  • Discitis / diagnosis
  • Discitis / etiology*
  • Discitis / microbiology
  • Drug Resistance, Fungal
  • Echinocandins
  • Humans
  • Lipopeptides
  • Magnetic Resonance Imaging
  • Male
  • Microbial Sensitivity Tests
  • Middle Aged
  • Peptides, Cyclic / therapeutic use
  • Pyrimidines / therapeutic use
  • Triazoles / therapeutic use
  • Voriconazole

Substances

  • Antifungal Agents
  • Echinocandins
  • Lipopeptides
  • Peptides, Cyclic
  • Pyrimidines
  • Triazoles
  • Amphotericin B
  • Caspofungin
  • Voriconazole